New study investigates how green tea could lead to a drug for tackling Covid-19

NewsGuard 100/100 Score

As India continues to be ravaged by the pandemic, a Swansea University academic is investigating how green tea could give rise to a drug capable of tackling Covid-19.

Dr Suresh Mohankumar carried out the research with colleagues in India during his time at JSS College of Pharmacy, JSS Academy of Higher Education and Research in Ooty prior to taking up his current role at Swansea University Medical School.

He said: "Nature's oldest pharmacy has always been a treasure of potential novel drugs and we questioned if any of these compounds could assist us in battling the Covid-19 pandemic?

"We screened and sorted a library of natural compounds already know to be active against other coronaviruses using an artificial intelligence-aided computer programme.

"Our findings suggested that one of the compounds in green tea could combat the coronavirus behind Covid-19."

The researchers' work has now been highlighted by online journal RSC Advances and has been included in its prestigious hot articles collection chosen by editors and reviewers.

Associate Professor Dr Mohankumar emphasized that the research was still in its early days and a long way from any kind of clinical application.

"The compound that our model predicts to be most active is gallocatechin, which is present in green tea and could be readily available, accessible, and affordable. There now needs to be further investigation to show if it can be proven clinically effective and safe for preventing or treating Covid-19.

"This is still a preliminary step, but it could be a potential lead to tackling the devastating Covid-19 pandemic.

Dr Mohankumar has worked in pharmacy education, research and administration around the world for more than 18 years and recently moved to Swansea to join its new MPharm programme.

This is fascinating research and demonstrates that natural products remain an important source of lead compounds in the fight against infectious diseases. I'm also really pleased to see this international research collaboration continuing now that Dr Mohankumar has joined the Pharmacy team."

Professor Andrew Morris, Head of Pharmacy

Dr Mohankumar added he is now looking forward to seeing how the work can be developed: "There now needs to be appropriate pre-clinical and clinical studies and we would welcome potential collaborators and partners to help carry this work forward."

Source:
Journal reference:

Selvaraj, J., et al. (2021) Identification of (2R,3R)-2-(3,4-dihydroxyphenyl)chroman-3-yl-3,4,5-trihydroxy benzoate as multiple inhibitors of SARS-CoV-2 targets; a systematic molecular modelling approach. RSC Advances. doi.org/10.1039/D1RA01603B.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Inflammatory disease not major risk factors for severe COVID-19, focus on comorbidities urged